Research Library

Browse, search, and filter the complete database of verified scientific literature

Topics:
6 results for “neuroprotection”
Year:–
Showing 6 of 180 articles

Filters

Category
Topics
Topics:
Study Type
Year Range
Year:–
Sort By
Neuroscience
NewDOI Resolved

Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease

Calleja-Conde J, Echeverry-Alzate V, Sanz-SanCristobal M et al.
Experimental neurology, 2026
Cross-sectional survey
Neuroscience
Publisher Confirmed

Preliminary analysis of ayahuasca-induced anatomical alterations in the somatosensory cortex of juvenile non-human primates subjected to chronic stress

Fernandes Pereira LR, Lira-Bandeira WG, Medeiros-Bandeira AS et al.
Translational Psychiatry, 2026
Open Access
Preclinical / in vivo
Pharmacology
DOI Resolved

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I, de Assis Braz G et al.
Archives of Toxicology, 2025
Preclinical in vitro
Pharmacology
PubMed Verified

Ayahuasca pretreatment prevents sepsis-induced anxiety-like behavior, neuroinflammation, and oxidative stress, and increases brain-derived neurotrophic factor

da Silva FS, Silva EAS, Sousa GM et al.
Journal of Psychiatric Research, 2023
15 citations
Preclinical in vivo
Pharmacology
PubMed Verified

Neuroprotective potential of ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease

Katchborian-Neto A, Santos MFC, Nicacio KJ et al.
Journal of Ethnopharmacology, 2020
75 citations
Preclinical in vitro
Pharmacology
PubMed Verified

The endogenous hallucinogen and trace amine N,N-dimethyltryptamine displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells

Szabo A, Kovacs A, Riba J et al.
Frontiers in Neuroscience, 2016
200 citationsOpen Access
Preclinical in vitro